Selective progesterone receptor modulators: An update

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1403-1415

  Benagiano, Giuseppe ^a   Bastianelli, Carlo ^a   Farris, Manuela ^a   Brosens, Ivo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LEUVEN INSTITUTE FOR FERTILITY AND EMBRYOLOGY   (Belgium)

Author keywords

Adenomyosis; Asoprisnil; Contraception; Emergency contraception; Endometriosis; Mifepristone; Proellex; Selective progesterone receptor modulators; Ulipristal acetate; Uterine leiomyomas

Indexed keywords

ASOPRISNIL; GESTRINONE; LEVONORGESTREL; MIFEPRISTONE; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR MODULATOR; TELAPRISTONE ACETATE; ULIPRISTAL;

ADENOMYOSIS; CONTRACEPTION; CYTOTOXICITY; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; EMERGENCY CONTRACEPTION; ENDOMETRIAL THICKNESS; ENDOMETRIOSIS; ENDOMETRIUM; HUMAN; NATURAL KILLER CELL; OVARY FOLLICLE DEVELOPMENT; OVULATION; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; REVIEW; UNPROTECTED SEX; UNWANTED PREGNANCY; UTERUS BLEEDING; UTERUS MYOMA; VAGINA RING; DRUG EFFECT; DRUG EFFICACY; FOLLICULAR PHASE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEIOMYOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY RATE; PREOPERATIVE CARE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEXUAL INTERCOURSE; UNPLANNED PREGNANCY;

ADENOMYOSIS; ASOPRISNIL; CONTRACEPTION; EMERGENCY CONTRACEPTION; ENDOMETRIOSIS; MIFEPRISTONE; PROELLEX; SELECTIVE PROGESTERONE RECEPTOR MODULATORS; ULIPRISTAL ACETATE; UTERINE LEIOMYOMAS;

ADENOMYOSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; CONTRACEPTION, POSTCOITAL; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, POSTCOITAL; ENDOMETRIOSIS; ESTRENES; FEMALE; HORMONE ANTAGONISTS; HUMANS; LEIOMYOMA; LEVONORGESTREL; MIFEPRISTONE; NORPREGNADIENES; OXIMES; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 84902272151     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.914494     Document Type: Review

References (106)

1. Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators: 1. Use during pregnancy. Expert Opin Pharmacother 2008;9:2487-96
2. Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators: 2. Use in reproductive medicine. Expert Opin Pharmacother 2008;9:2473-85
3. Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators: 3. Use in oncology, endocrinology, psychiatry. Expert Opin Pharmacother 2008;9:2459-72
4. Mozzanega B, Gizzo S, Di Gangi S, et al. Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception. Reprod Sci 2014. [Epub ahead of print]
5. Dunn S, Guilbert E, Burnett M, et al. Society of Obstetricians and Gynecologists of Canada. Emergency contraception: no. 280 (replaces No. 131, August 2003). Int J Gynaecol Obstet 2013;120:102-7
6. Westley E, Kapp N, Palermo T, Bleck J. A review of global access to emergency contraception. Int J Gynaecol Obstet 2013;123:4-6
7. Koyama A, Hagopian L, Linden J. Emerging options for emergency contraception. Clin Med Insights Reprod Health 2013;7:23-35
8. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013;29(Suppl 1):1-14
9. Lalitkumar PG, Berger C, Gemzell-Danielsson K. Emergency contraception. Best Pract Res Clin Endocrinol Metab 2013;27:91-101
10. Committee on Adolescence. Emergency contraception. Pediatrics 2012;130:1174-82
11. Glasier A. Emergency contraception: clinical outcomes. Contraception 2013;87:309-13
12. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2000;360:1803-10
13. World Health Organization. Task Force on Post-Ovulatory Methods for Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 1999;353:697-702
14. von Hertzen H, Van Look PFA. Research on new methods of emergency contraception. Int Fam Plann Perspect 1996;22:62-8
15. European Medicines Agency (EMeA). Ref.: EMEA/261787/2009. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/001027/WC500023673.pdf [Accessed on 8 February 2014]
16. US Food and Drug Administration Press release: FDA approves Ella™ tablets for prescription emergency contraception. 2010. Available from: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm222428.htm [Accessed on 8 February 2014]
17. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089-97
18. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555-62
19. Benagiano G, von Hertzen H. Towards more effective emergency contraception? Lancet 2010;375:527-8
20. Fine P, Mathe H, Ginde S, et al. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257-63
21. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363-7
22. Moreau C, Trussell J. Results from pooled phase III studies of ulipristal acetate for emergency contraception. Contraception 2012;86:673-80
23. Munuce MJ, Zumoffen C, Cicaré J, et al. Effect of exposure to ulipristal acetate on sperm function. Eur J Contracept Reprod Health Care 2012;17(6):428-37
24. Thomas CM, Cameron S. Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC. BMJ Open 2013;3:e003815
25. Bayer LL, Edelman AB, Caughey AB, Rodriguez MI. The price of emergency contraception in the United States: what is the cost-effectiveness of ulipristal acetate versus single-dose levonorgestrel? Contraception 2013;87:385-90
26. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Chochrane Database Syst Rev 2012;8:CD001324
27. Levy DP, Jager M, Kapp N, Abitbol JL. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. Contraception 2014. [Epub ahead of print]
28. Wu S, Dong J, Cong J, et al. Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstet Gynecol 2010;115:740-4
29. Taneepanichskul S. Emergency contraception with mifepristone 10 mg in Thai women. J Med Assoc Thai 2009;92:999-1002
30. Zhu HX, Zhang WW, Zhuang YL, Huang LL. Mifepristone as an anti-implantation contraceptive drug: roles in regulation of uterine natural killer cells during implantation phase. Am J Reprod Immunol 2009;61:68-74
31. Chen XY, Zhuang YL, Li L, et al. The effect of mifepristone on the peripheral blood natural killer cell's cytotoxicity and expression of CD94/NKG2A and NKG2D during the implantation phase. Fertil Steril 2010;93:2615-20
32. Zhou F, Chen XY, Zhuang YL, et al. Low-dose mifepristone increases uterine natural killer cell cytotoxicity and perforin expression during the receptive phase. Fertil Steril 2011;96:649-53
33. Chen Y, Wang Y, Zhuang Y, et al. Mifepristone increases the cytotoxicity of uterine natural killer cells by acting as a glucocorticoid antagonist via ERK activation. PLoS One 2012;7:e36413
34. Zhou F, Liang Y, Qian ZD, et al. Low-dose mifepristone increases uterine expression of aquaporin 1/aquaporin 2 at the time of implantation. Contraception 2013;87:844-9
35. Gemzell-Danielsson K, Meng C-X. Emergency contraception: potential role of ulipristal acetate. Int J Womens Health 2010;2:53-61
36. Marions L, Hultenby K, Lindell I, et al. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65-71
37. Keenan JA. Ulipristal acetate: contraceptive or contragestive? Ann Pharmacother 2011;45:813-15
38. Brache V, Cochon L, Jesam C, et al. Immediate preovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010;25:2256-63
39. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88:611-18
40. Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010;93:2035-41
41. Stratton P, Hartog B, Hajizadeh N, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092-9
42. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010;82:442-52
43. Agarwal M, Das V, Agarwal A, et al. Evaluation of mifepristone as a once a month contraceptive pill. Am J Obstet Gynecol 2009;200:e27-9
44. Chen Y, Wang W, Zhuang Y, et al. Effects of low-dose mifepristone administration in two different 14-day regimens on the menstrual cycle and endometrial development: a randomized controlled trial. Contraception 2011;84:64-70
45. Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception 2013;87:314-18
46. Brache V, Sitruk-Ware R, Williams A, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception 2012;85:480-8
47. Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-704
48. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-8
49. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24
50. Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009;49:77-83
51. Fraser IS. Low-dose mifepristone: effects on the endometrium. Aust N Z J Obstet Gynaecol 2009;49:77-83
52. Fiscella J, Bonfiglio T, Winters P, et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011;42:947-53
53. Helmestam M, Lindgren KE, Stavreus-Evers A, Olovsson M. Mifepristone-exposured human endometrial endothelial cells in vitro. Reprod Sci 2014;21(3):408-14
54. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22:450-9
55. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-9
56. Ravet S, Munaut C, Blacher S, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab 2008;93:4525-31
57. Wei Q, Levens ED, Stefansson L, Nieman LK. Indian Hedgehog and its targets in human endometrium: menstrual cycle expression and response to CDB-2914. J Clin Endocrinol Metab 2010;95:5330-7
58. Brenner RM, Slayden OD, Nath A, et al. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010;81:336-42
59. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31:556-69
60. Donnez J, Tomaszewski J, Vázquez F, et al. for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32
61. Wilkens J, Male V, Ghazal P, et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. J Immunol 2013;191:2226-35
62. Zhou YF, Matsuda M, Mori T, et al. Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice. Life Sci 2000;67:2713-20
63. The National Knowledge Infrastructure of China (CNKI). Xuemei C, Linxiao H, Li'e H, et al. The clinical effect and safety of long period and low dosage Mifepristone to perimenopausal uterine adenomyosis (Department of Gynaecology, Shilong People's Hospital of Dongguan City, Dongguan 523326, China). Available from: http://en.cnki. com.cn/Article-en/CJFDTOTAL-YYCY200910011.htm [Accessed on 10 February 2014]
64. Guo SW, Liu M, Shen F, Liu X. Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women's Health (Lond Engl) 2011;7:51-70
65. The National Knowledge Infrastructure of China (CNKI). Endometriosis. Available from: http://en.cnki.com.cn/Article-en/CJFDTOTAL-YYCY200910011.htm [Accessed on 10 February 2014]
66. Mei L, Bao J, Tang L, et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci 2010;39:421-7
67. Li X, Bao Y, Fang P, et al. Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model. Arch Gynecol Obstet 2012;286:939-46
68. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-17
69. Yen SSC. Clinical use of RU 486 in the treatment of uterine fibroids. In: Donaldson MS, Dorflinger L, Brown SS, Benet LS, editors, Clinical applications of Mifepristone (RU 486) and other antiprogestins. National Academy Press, Washington; 1993. p. 189-209
70. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6
71. Carbonell Esteve JL, Acosta R, Heredia B, et al. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008;112:1029-36
72. Eisinger SH, Fiscella J, Bonfiglio T, et al. Open-label study of ultra-low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009;146:215-18
73. Carbonell Esteve JL, Riverón AM, Cano M, et al. Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery. Int J Womens Health 2012;4:75-84
74. Esteve JL, Acosta R, Pérez Y, et al. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012;161:202-8
75. Carbonell JL, Acosta R, Pérez Y, et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health 2013;5:115-24
76. Esteve JL, Acosta R, Pérez Y, et al. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int J Womens Health 2013;5:361-9
77. Carbonell JL, Acosta R, Pérez Y, et al. Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months post-treatment follow-up: randomized clinical trial. ISRN Obstet Gynecol 2013;2013:649030
78. Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009;24:1870-9
79. Mukherjee S, Chakraborty S. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri. Niger Med J 2011;52:150-2
80. Seth S, Goel N, Singh E, et al. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health 2013;4:22-6
81. Kulshrestha V, Kriplani A, Agarwal N, et al. Low dose mifepristone in medical management of uterine leiomyoma-an experience from a tertiary care hospital from north India. Indian J Med Res 2013;137:1154-62
82. Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet 2010;109:121-4
83. Tristan M, Orozco LJ, Steed A, et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev 2012;8:CD007687
84. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381-7
85. Shen Q, Hua Y, Jiang W, et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 2013;100:1722-6; e1-10
86. Yerushalmi GM, Gilboa Y, Jakobson-Setton A, et al. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril 2014;101:496-500
87. Engman M, Varghese S, Lagerstedt Robinson K, et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One 2013;8:e80114
88. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008;14:181-91
89. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36
90. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95:767-72.e2
91. Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol 2012;2012:436174
92. Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther 2012;29:655-63
93. Koskas M, Derrien J. [Medical treatment of symptomatic uterine leiomyomata in premenopausal woman]. Presse Med 2013;42:1122-6.[Article in French]
94. Monleón Sancho J, Romaguera E, Romero A, et al. [Ulipristal acetate, 5mg: a new alternative]. Med Clin (Barc) 2013;141(Suppl 1):40-6.[Article in Spanish]
95. Melis GB, Piras B, Marotto MF, et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol 2012;8:901-8
96. Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother 2013;14:2079-85
97. DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-32
98. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
99. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91:1296-304
100. Wang J-Y, Ohara N, Zhuo Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFb3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006;21:1869-77
101. Sasaki H, Ohara N, Xu Q, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007;92:616-23
102. Morikawa A, Ohara N, Qin X, et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008;23:944-51
103. Xu Q, Ohara N, Liu J, et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Endocrinol Metab 2007;293:E1002-11
104. Wilkens J, Williams AR, Chwalisz K, et al. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Hum Reprod 2009;24:1036-44
105. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-412
106. Brosens J, Campo R, Gordts S, Brosens I. Submucous and outer myometrium leiomyomas are two distinct clinical entities. Fertil Steril 2003;79:1452-4